SUMMARY Oral formulations of 5-aminosalicylic acid (mesalazine) appear less toxic than sulphasalazine. We have therefore compared sulphasalazine, low dose mesalazine and high dose mesalazine in the treatment of mild to moderate relapse of ulcerative colitis. Sixty one patients (32 men, aged 20-78 years) were randomly allocated to sulphasalazine 2 g daily, mesalazine 800 mg daily, or mesalazine 2.4 g daily in a double blind, double dummy, four week trial. Groups were comparable for age, sex, extent of disease, and pretrial sulphasalazine intake. Four patients were unable to complete the study because of treatment failure (two taking sulphasalazine and two high dose mesalazine). A further two patients taking sulphasalazine developed side effects necessitating withdrawal. Within treatment comparisons revealed significant improvement of: sigmoidoscopic grade in the sulphasalazine group; rectal bleeding, sigmoidoscopic and histological grade in the low dose mesalazine group; stool frequency, rectal bleeding and sigmoidoscopic grade in the high dose mesalazine group. Greater improvement in rectal bleeding (p<005) and sigmoidoscopic appearances (p<005) occurred in patients taking high dose mesalazine than in those taking sulphasalazine. In two patients taking high dose mesalazine minor rises of plasma creatinine concentrations occurred, suggesting the need to monitor renal function.
its mode of action is thought to be predominantly topical6 oral formulations have been developed to deliver 5-ASA to its site of action.
We have studied a delayed release form of 5-ASA (mesalazine) which relies on its coating, Eudragit S, to release 5-ASA in the colon. Coat dissolution is pHdependent occurring rapidly above pH 7, the prevailing pH of the distal small intestine and colon. "7-' The aim of the present study was to compare sulphasalazine, equivalent dose mesalazine and high dose mesalazine in the treatment of mild to moderate ulcerative colitis relapse. On entry to the study the three groups were matched for stool frequency, rectal bleeding, sigmoidoscopic, and histological grade. Within treatment comparisons revealed significant improvement of: sigmoidoscopic grading above 5 cm in the SSZ group; rectal bleeding and all sigmoidoscopic grades in the low dose mesalazine group and stool frequency, rectal bleeding and all sigmoidoscopic grades in the high dose mesalazine group (Table 3 ). Significant improvement in histological grade occurred only in the low dose mesalazine group although significance in the high dose group approached the 5% level. Four patients, two allocated SSZ and two high dose mesalazine, suffered significant clinical deterioration and were unable to complete the four week study period.
Between treatment differences were only statistically significant when comparing the high dose mesalazine and SSZ group. On trial entry 95% of patients allocated SSZ, 85% allocated low dose 
Median (range); within treatment significance: *p<0005; tp<001.
mesalazine and 95% allocated high dose mesalazine were passing three or more stools per day. On completion of the study the percentages had fallen to 47%, 30%, and 19% respectively (p<01 high dose mesalazine versus SSZ). All patients were passing blood at least once daily on entry to the study. Improvement in rectal bleeding occurred in 47% taking SSZ, 75% taking low dose, and 81% taking high dose mesalazine (p<0.05 high dose mesalazine versus SSZ). Symptomatic remission (resolution of rectal bleeding and three or less stools per day) was seen in 21%, 30%, and 43% of the groups respectively (p<02).
All patients included in the study had sigmoidoscopic evidence of active disease (grade 2 or more, Table 1 ). After four weeks' treatment significant improvement (grade 1 or less) was seen in 5% of patients receiving SSZ, 25% receiving low dose and 33% high dose mesalazine (p<0-05 high dose mesalazine versus SSZ). No significance between treatment differences was apparent with respect to histological grade.
Pretrial SSZ intake appeared to be a major predictor of treatment outcome. Of the 23 patients taking SSZ at trial entry, only 13 patients improved and only two achieved symptomatic remission during the four week trial. In the group of 37 patients not taking SSZ at trial entry, however, 31 patients improved and 17 achieved symptomatic remission (p<0005). The influence of pretrial SSZ intake on treatment outcome by treatment group is shown in Table 4 .
SIDE EFFECTS AND LABORATORY VALUES
Two patients were unable to complete the study because of drug related side effects. One patient 
